search
Back to results

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
telmisartan, valsartan
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring hypertension, telmisartan, valsartan, boehringer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 1. Mild-to-moderate hypertension defined as a baseline mean seated DBP of greater than or equal to 95 mm Hg and less than or equal to 109 mm Hg and a baseline 24-hour ABPM mean DBP of greater than or equal to 85 mm Hg. Exclusion Criteria: Pre-menopausal women (last menstruation = 1 year prior to signing informed consent) who: Are not surgically sterile. Are nursing. Are of child-bearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the study. Acceptable methods of birth control include IUD, oral, implantable or injectable contraceptives. No exceptions will be made. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 A.M. Mean sitting SBP =180 mm Hg or mean sitting DBP =110 mm Hg during any visit of the placebo run-in period. Known or suspected secondary hypertension (i.e., pheochromocytoma). Hepatic and/or renal dysfunction as defined by the following laboratory parameters: SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range. Serum creatinine > 2.3 mg/dL (or > 203 µmol/l). Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney. Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia. Uncorrected volume depletion. Primary aldosteronism. Hereditary fructose intolerance. Biliary obstructive disorders. Congestive heart failure (NYHA functional class CHF III-IV). Unstable angina within the past three months prior to signing the informed consent form. Stroke within the past six months prior to signing the informed consent form. Myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form. PTCA (percutaneous transluminal coronary revascularization) within the past three months prior to signing the informed consent form. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve. Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C =10%. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists. History of drug or alcohol dependency within 6 months prior to signing the informed consent form. Chronic administration of any medications known to affect blood pressure, except medication allowed by the protocol. Any investigational therapy within one month of signing the informed consent form. Known hypersensitivity to any component of the formulations. Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication. Inability to comply with the protocol.

Sites / Locations

  • Memorial Research Medical Clinic
  • National Research Institute
  • Orange County Research Center
  • University of Conn. Health Services Center, Hypertension and Vascular Disease
  • Alan Graff
  • Greater Ft. Lauderdale Heart Group Research
  • Orlando Clinical Research Center
  • So. Clinical Research and Management, Inc.
  • Rush Presbyterian/St. Luke's Medical Center
  • University of Maryland/Nephrology Clinical Research Unit
  • Washington University
  • Oklahoma Cardiovascular and Hypertension Center
  • Michael A. Azorr, M.D.
  • Harleysville Medical Associates
  • Trinity Hypertension Research Institute/Punzi Medical Center
  • UW Health/Physicians Plus Center for Clinical Trials
  • Heart Health Institute
  • Dr. Dennis O'Keefe
  • Dr. William Booth
  • MSHJ Research Assoc.
  • Dr. Joseph Berlingieri
  • Dr. William Mahoney
  • BBM Clinical Research Ltd.
  • Dr. Richard Tytus
  • Total Concept Health Care
  • Centre for Activity and Aging
  • Dr. Martyn Chilvers
  • Sunnybrook & Women's College Health Centre
  • Theradev Clinical Research, Inc.
  • Invascor, Longueuil
  • Hotel Dieu de St-Jerome
  • Centre de Cardiologie
  • Centre Hospital Quebec - PAC CHUL Unite de Recherche
  • Q&T Research
  • Royal University Hospital

Outcomes

Primary Outcome Measures

Change in the 24-hour mean diastolic blood pressure (DBP), as measured by ABPM after a missed dose
Change in the mean DBP during the last 6 hours of the 24-hour dosing interval, as measured by ABPM after an active dose of study medication

Secondary Outcome Measures

Change in 24-hour ABPM mean systolic blood pressure (SBP) after a missed dose
Change in the last 6 hour ABPM mean SBP measured after a dose of active treatment
Changes in ABPM mean DBP and SBP during other periods of the 24-hour dosing interval after an active dose
Changes in ABPM mean DBP and SBP during other periods of the 24-hour dosing interval after a missed dose
Changes in in-clinic mean seated trough DBP and SBP as measured by manual cuff sphygmomanometer after a missed dose
Changes in in-clinic mean seated trough DBP and SBP as measured by manual cuff sphygmomanometer after an active dose
Responder rates based on ABPM
Responder rates based on in-clinic trough cuff blood pressures

Full Information

First Posted
May 2, 2002
Last Updated
October 31, 2013
Sponsor
Boehringer Ingelheim
Collaborators
GlaxoSmithKline, Bayer
search

1. Study Identification

Unique Protocol Identification Number
NCT00034840
Brief Title
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Official Title
A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
October 2001 (undefined)
Primary Completion Date
August 2002 (Actual)
Study Completion Date
August 2002 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim
Collaborators
GlaxoSmithKline, Bayer

4. Oversight

5. Study Description

Brief Summary
The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
hypertension, telmisartan, valsartan, boehringer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
490 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
telmisartan, valsartan
Primary Outcome Measure Information:
Title
Change in the 24-hour mean diastolic blood pressure (DBP), as measured by ABPM after a missed dose
Time Frame
after 6 to 8 weeks
Title
Change in the mean DBP during the last 6 hours of the 24-hour dosing interval, as measured by ABPM after an active dose of study medication
Time Frame
after 6 to 8 weeks
Secondary Outcome Measure Information:
Title
Change in 24-hour ABPM mean systolic blood pressure (SBP) after a missed dose
Time Frame
after 6 to 8 weeks
Title
Change in the last 6 hour ABPM mean SBP measured after a dose of active treatment
Time Frame
after 6 to 8 weeks
Title
Changes in ABPM mean DBP and SBP during other periods of the 24-hour dosing interval after an active dose
Time Frame
8 weeks
Title
Changes in ABPM mean DBP and SBP during other periods of the 24-hour dosing interval after a missed dose
Time Frame
8 weeks
Title
Changes in in-clinic mean seated trough DBP and SBP as measured by manual cuff sphygmomanometer after a missed dose
Time Frame
8 weeks
Title
Changes in in-clinic mean seated trough DBP and SBP as measured by manual cuff sphygmomanometer after an active dose
Time Frame
8 weeks
Title
Responder rates based on ABPM
Time Frame
after 6 to 8 weeks
Title
Responder rates based on in-clinic trough cuff blood pressures
Time Frame
after 6 to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Mild-to-moderate hypertension defined as a baseline mean seated DBP of greater than or equal to 95 mm Hg and less than or equal to 109 mm Hg and a baseline 24-hour ABPM mean DBP of greater than or equal to 85 mm Hg. Exclusion Criteria: Pre-menopausal women (last menstruation = 1 year prior to signing informed consent) who: Are not surgically sterile. Are nursing. Are of child-bearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the study. Acceptable methods of birth control include IUD, oral, implantable or injectable contraceptives. No exceptions will be made. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 A.M. Mean sitting SBP =180 mm Hg or mean sitting DBP =110 mm Hg during any visit of the placebo run-in period. Known or suspected secondary hypertension (i.e., pheochromocytoma). Hepatic and/or renal dysfunction as defined by the following laboratory parameters: SGPT (ALT) or SGOT (AST) > 2 times the upper limit of normal range. Serum creatinine > 2.3 mg/dL (or > 203 µmol/l). Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney. Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia. Uncorrected volume depletion. Primary aldosteronism. Hereditary fructose intolerance. Biliary obstructive disorders. Congestive heart failure (NYHA functional class CHF III-IV). Unstable angina within the past three months prior to signing the informed consent form. Stroke within the past six months prior to signing the informed consent form. Myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form. PTCA (percutaneous transluminal coronary revascularization) within the past three months prior to signing the informed consent form. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve. Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C =10%. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists. History of drug or alcohol dependency within 6 months prior to signing the informed consent form. Chronic administration of any medications known to affect blood pressure, except medication allowed by the protocol. Any investigational therapy within one month of signing the informed consent form. Known hypersensitivity to any component of the formulations. Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication. Inability to comply with the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim Study Coordinator
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
Memorial Research Medical Clinic
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Orange County Research Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
University of Conn. Health Services Center, Hypertension and Vascular Disease
City
Farmington
State/Province
Connecticut
ZIP/Postal Code
06030
Country
United States
Facility Name
Alan Graff
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
Facility Name
Greater Ft. Lauderdale Heart Group Research
City
Ft. Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
Facility Name
Orlando Clinical Research Center
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
So. Clinical Research and Management, Inc.
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30904
Country
United States
Facility Name
Rush Presbyterian/St. Luke's Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
University of Maryland/Nephrology Clinical Research Unit
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Washington University
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Oklahoma Cardiovascular and Hypertension Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73132
Country
United States
Facility Name
Michael A. Azorr, M.D.
City
Portland
State/Province
Oregon
ZIP/Postal Code
97232
Country
United States
Facility Name
Harleysville Medical Associates
City
Harleysville
State/Province
Pennsylvania
ZIP/Postal Code
19438
Country
United States
Facility Name
Trinity Hypertension Research Institute/Punzi Medical Center
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Facility Name
UW Health/Physicians Plus Center for Clinical Trials
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53715
Country
United States
Facility Name
Heart Health Institute
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2E 7C5
Country
Canada
Facility Name
Dr. Dennis O'Keefe
City
Mount Pearl
State/Province
Newfoundland and Labrador
ZIP/Postal Code
A1N 2C3
Country
Canada
Facility Name
Dr. William Booth
City
Antigonish
State/Province
Nova Scotia
ZIP/Postal Code
B2G 2C2
Country
Canada
Facility Name
MSHJ Research Assoc.
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3K 5R3
Country
Canada
Facility Name
Dr. Joseph Berlingieri
City
Burlington
State/Province
Ontario
ZIP/Postal Code
L7R 2H3
Country
Canada
Facility Name
Dr. William Mahoney
City
Corunna
State/Province
Ontario
ZIP/Postal Code
N0N 1G0
Country
Canada
Facility Name
BBM Clinical Research Ltd.
City
Courtice
State/Province
Ontario
ZIP/Postal Code
L1E 3C3
Country
Canada
Facility Name
Dr. Richard Tytus
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8M 1K7
Country
Canada
Facility Name
Total Concept Health Care
City
Kitchener
State/Province
Ontario
ZIP/Postal Code
N2C 2N9
Country
Canada
Facility Name
Centre for Activity and Aging
City
London
State/Province
Ontario
ZIP/Postal Code
N6G 2M3
Country
Canada
Facility Name
Dr. Martyn Chilvers
City
Sarnia
State/Province
Ontario
ZIP/Postal Code
N7T 4X3
Country
Canada
Facility Name
Sunnybrook & Women's College Health Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Facility Name
Theradev Clinical Research, Inc.
City
Granby
State/Province
Quebec
ZIP/Postal Code
J2G 8Z9
Country
Canada
Facility Name
Invascor, Longueuil
City
Longueuil
State/Province
Quebec
ZIP/Postal Code
J4N 1E1
Country
Canada
Facility Name
Hotel Dieu de St-Jerome
City
Saint Jerome
State/Province
Quebec
ZIP/Postal Code
J7Z 5T3
Country
Canada
Facility Name
Centre de Cardiologie
City
Saint Lambert
State/Province
Quebec
ZIP/Postal Code
J4P 2H4
Country
Canada
Facility Name
Centre Hospital Quebec - PAC CHUL Unite de Recherche
City
Sainte-Foy
State/Province
Quebec
ZIP/Postal Code
G1V 4G2
Country
Canada
Facility Name
Q&T Research
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 4J6
Country
Canada
Facility Name
Royal University Hospital
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 0W8
Country
Canada

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.327_U03-3143.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.327_literature.pdf
Description
Related Info

Learn more about this trial

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

We'll reach out to this number within 24 hrs